Leptin receptor

Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022

Retrieved on: 
Monday, September 19, 2022
Adult, Bardet–Biedl syndrome, Endocrine Society, Leptin receptor, Microdeletion syndrome, Department, MC4R, FDA, UCL Great Ormond Street Institute of Child Health, MD, Pediatrics, Adolescence, Poster, European Society for Medical Oncology, Obesity, Patient, Mental health, BBS, POMC, Very early onset inflammatory bowel disease, Nasdaq, Ageing, Caregiver, EC, Polyphagia, ESPE, LEPR, GLOBE, Pediatric endocrinology, Disease, Pharmaceutical industry, Residential care, Setmelanotide, Pediatric nursing, Proopiomelanocortin, Rhythm

BOSTON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, announced the presentation of new findings on the burden of hyperphagia and obesity on patients with Bardet-Biedl syndrome (BBS) and their caregivers during the 60th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE 2022) held in Rome on Sept. 15 to 17.

Key Points: 
  • Rhythm and its collaborators delivered one poster and three oral presentations during ESPE 2022, including data from new analyses that showed setmelanotide achieved substantial weight loss benefit in adolescent and pediatric patients with rare MC4R pathway diseases across three separate pivotal trials.
  • CARE-BBS participants at the time of the survey were residents of the United States (n=60), Canada (n=62), United Kingdom (n=59) or Germany (n=61).
  • In addition, the findings illustrate how the negative impact of hyperphagia on caregivers affects family dynamics, emotional well-being, and caregiver employment.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases.

Rhythm Pharmaceuticals to Present at 2021 Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Thursday, August 5, 2021
Proprotein convertase 1, Back pain, Suicidal ideation, European Commission, Obesity, Central nervous system, Safety, Royal commission, Sexual arousal, Investor relations, Skin, Risk, Private Securities Litigation Reform Act, EC, Pigment, Food and Drug Administration, Pregnancy, Regulation of tobacco by the U.S. Food and Drug Administration, Security (finance), Headache, Diagnosis, Incidence, Data analysis, Upper respiratory tract infection, Depression, Fatigue, Nausea, Food, Conference, Company, GLOBE, U.S. Securities and Exchange Commission, Webcast, Abdominal pain, Genetic testing, Hunger, Patient, COVID-19, Vomiting, Diarrhea, Fetus, Canaccord Genuity, Adult, Nasdaq, DNA, Physician, Leptin receptor, Pharmaceutical industry, Dietary supplement, Birth control

BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8 a.m.

Key Points: 
  • BOSTON, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on Thursday, August 12, 2021 at 8 a.m.
  • A replay of the webcast will be available on the Rhythm website for 30 days following the presentation.
  • Rhythm is a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity.
  • Rhythm is advancing a broad clinical development program for setmelanotide in other rare genetic diseases of obesity.